Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Net Loss for the Segment (Details) $ in Thousands |
3 Months Ended | |
|---|---|---|
|
Mar. 31, 2026
USD ($)
|
Mar. 31, 2025
USD ($)
|
|
| Summary of Significant Accounting Policies and Recent Accounting Pronouncements | ||
| Number of reportable segments | 1 | |
| Number of operating segments | 1 | |
| Service revenue - related party | $ 293 | $ 1,926 |
| Cost of service revenue - related party | 198 | 1,378 |
| General and administrative | 6,158 | 6,348 |
| AAV-hAQP1 | 2,353 | 4,852 |
| AAV-GAD | 847 | 1,459 |
| Other ocular diseases | 1,445 | |
| Manufacturing | 16,422 | 17,359 |
| Gene regulation | 1,366 | 2,286 |
| Neurodegenerative diseases | 297 | 426 |
| Preclinical ocular diseases | 1,145 | 625 |
| Other research and development | 5,662 | (624) |
| Share-based compensation | 3,654 | 4,887 |
| Depreciation and amortization | 3,008 | 3,081 |
| Total operating expenses | 41,110 | 43,522 |
| Other segment items | (5,496) | 1,615 |
| Segment net loss | (46,313) | (39,981) |
| Net Income (Loss) | $ (46,313) | $ (39,981) |
| X | ||||||||||
- Definition Amount of expense for clinical trials for AAV-hAQP1 drug substances. No definition available.
|
| X | ||||||||||
- Definition Amount of expense for clinical trials for AAV-GAD drug substances. No definition available.
|
| X | ||||||||||
- Definition Other segment items of income (expense). No definition available.
|
| X | ||||||||||
- Definition Amount of expense for pre-clinical research relating to gene regulation. No definition available.
|
| X | ||||||||||
- Definition Amount of expense for pre-clinical research relating to neurodegenerative diseases. No definition available.
|
| X | ||||||||||
- Definition Amount of expense for pre-clinical research relating to preclinical ocular diseases. No definition available.
|
| X | ||||||||||
- Definition Amount of expense for research and development pertaining to clinical trials for drug substances. No definition available.
|
| X | ||||||||||
- Definition Amount of expense for research and development pertaining to manufacturing of drug substances. No definition available.
|
| X | ||||||||||
- Definition Amount of expense for research and development classified as other. No definition available.
|
| X | ||||||||||
- Definition The segment total of research and development expenses. No definition available.
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. No definition available.
|
| X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The aggregate total amount of expenses directly related to the marketing or selling of products or services. No definition available.
|
| X | ||||||||||
- Definition Amount of noncash expense for share-based payment arrangement. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|